Perspective Therapeutics Receivables

The latest receivables for ISR is $58K as of March 2026. That compares with $78K in the prior-year period — down 25.6% year over year. Investors often review this figure alongside Perspective Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, ISR's receivables moved from $78K to $58K — a 25.6% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Perspective Therapeutics's operating scale or balance-sheet position.

A receivables figure of $58K for ISR is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting ISR's receivables ($58K), review year-over-year change from $78K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Perspective Therapeutics's receivables against similar Industrials names. You can also browse sector and industry screens on Stockcircle for a broader set of Industrials companies and their key multiples and fundamentals.